Lee:Literature Transporters: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
|||
(22 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Lee_lab}} | |||
{|cellspacing="5" cellpadding="10" style="background:#3674C2; width: 1000px;" | |||
|-valign="top" | |||
|style="background:#ffffff"| | |||
<font color=green> Feel free to add articles ...</font> | <font color=green> Feel free to add articles ...</font> | ||
Line 21: | Line 9: | ||
==Transporters general review== | ==Transporters general review== | ||
# Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR. Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab Rev. 2009;41(1):27-65. (PMID: 19514970) | |||
#1 pmid=17404808 | # Oswald S, Grube M, Siegmund W, Kroemer HK. Transporter-mediated uptake into cellular compartments. Xenobiotica. 2007 Oct-Nov;37(10-11):[http://informahealthcare.com/doi/pdf/10.1080/00498250701570251 1171-95]. | ||
# | # Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009 Sep;26(9):[http://www.springerlink.com/content/n1qm3g5549917117/fulltext.pdf 2039-54]. | ||
# | # Li P, Wang GJ, Robertson TA, Roberts MS. Liver transporters in hepatic drug disposition: an update. Curr Drug Metab. 2009 Jun;10(5):[http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?hid=18&sid=20430974-aa00-4ea0-87e3-185ed4b37015%40sessionmgr12&vid=2 482-98]. | ||
# Oostendorp RL, Beijnen JH, Schellens JH. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev. 2009 Apr;35(2):[http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WC8-4TVG1N0-1-7&_cdi=6732&_user=16764&_pii=S0305737208002879&_origin=search&_coverDate=04%2F30%2F2009&_sk=999649997&view=c&wchp=dGLzVtz-zSkWA&md5=f0bb86626bc9d7087948101387e11a74&ie=/sdarticle.pdf 137-47]. | |||
# Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica. 2008 Jul;38(7-8):[http://informahealthcare.com/doi/pdf/10.1080/00498250801927435 889-935]. | |||
==OATP family general review== | # Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications.Pharm Res. 2007 Oct;24(10):1803-23. (pmid=17404808) | ||
# Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009 Dec;50(12):2340-57. (pmid=19498215) | |||
# | # DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf. 2005;28(9):789-801. (pmid=16119972) | ||
# | |||
==OATP family general review== | |||
# Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004 Feb;447(5):[http://www.springerlink.com/content/blyl0rxlannfjjfe/fulltext.pdf 653-65]. (pmid=14579113) | |||
# Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007 Jul;8(7):787-802. (pmid=18240907) | |||
==OATP knockout models== | |||
# Van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, Schinkel AH.Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.J Clin Invest. 2010 Aug 2;120(8):2942-52. doi: 10.1172/JCI42168. Epub 2010 Jul 19.[http://www.jci.org/articles/view/42168/pdf 2942-2952](PMID=20644253) | |||
# Van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, Schinkel AH.High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.Clin Cancer Res. 2010 Nov 19. [Epub ahead of print][http://clincancerres.aacrjournals.org/content/early/2010/11/19/1078-0432.CCR-10-1980.full.pdf+html] (PMID: 21097690) | |||
==Analysis: Methods== | |||
# Koellensperger G, Hann S.Ultra-fast HPLC-ICP-MS analysis of oxaliplatin in patient urine. Anal Bioanal Chem. 2010 May;397(1):401-6. Epub 2010 Feb 19.[http://www.springerlink.com/content/er871g7261240011/fulltext.pdf 401-406] (PMID: 20165835) | |||
==OATP1B3== | ==OATP1B3== | ||
# Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA: Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001, 121:1185-1190. | |||
# | # Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, et al.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001, 120:1689-1699. | ||
# | # Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA: Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 2002, 122:1954-1966. | ||
# | # Cui Y, Walter B: Influence of albumin binding on the substrate transport mediated by human hepatocyte transporters OATP2 and OATP8. J Gastroenterol 2003, 38:60-68. | ||
#4 | # Letschert K, Keppler D, Konig J: Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004, 14:441-452. | ||
# | # Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005, 4:815-818. | ||
# | # Al Sarakbi W, Mokbel R, Salhab M, Jiang WG, Reed MJ, Mokbel K: The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Res 2006, 26:4985-4990. | ||
#7 | # Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H, Sato M, Matsuura M, Saga T, Unno M, et al.: Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006, 47:1196-1202. | ||
#8 | # Lockhart AC, Harris E, LaFleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W: Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol 2008, 1:1-7. | ||
# | # Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, et al.: Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 2008, 68:10315-10323. | ||
#10 | # Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, Taura K, Yasuchika K, Nitta T, Ikai I, et al.: Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009, 44:793-798. | ||
# | # Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, Hishinuma T, Mano N: Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 2008, 260:163-169. | ||
#12 pmid= | # Baldes C, Koenig P, Neumann D, Lenhof HP, Kohlbacher O, Lehr CM: Development of a fluorescence-based assay for screening of modulators of human Organic Anion Transporter 1B3 (OATP1B3). Eur J Pharm Biopharm 2005. | ||
# | # Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ: Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 2003, 371:897-905. | ||
# Muto M, Onogawa T, Suzuki T, Ishida T, Rikiyama T, Katayose Y, Ohuchi N, Sasano H, Abe T, Unno M: Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 2007, 98:1570-1576. | |||
# | # Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005, 33:434-439. | ||
# Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, et al.: Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008, 14:3312-3318. | |||
# Gui C, Hagenbuch B: Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. Biochemistry 2008, 47:9090-9097. | |||
# Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008, 99:967-972. | |||
# Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T, Tamai I: Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 2010. | |||
# Ichihara S, Kikuchi R, Kusuhara H, Imai S, Maeda K, Sugiyama Y: DNA methylation profiles of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res 2010, 27:510-516. | |||
==P-glycoprotein (MDR1)== | |||
# Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov Today. 2007 Oct;12(19-20):[http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T64-4PMJB7Y-1-5&_cdi=5020&_user=16764&_pii=S1359644607003030&_origin=search&_coverDate=10%2F31%2F2007&_sk=999879980&view=c&wchp=dGLbVlz-zSkzS&md5=5d885a3c7361f7744bee594979e5f2c6&ie=/sdarticle.pdf 833-7]. (pmid=17933684) | |||
# Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today. 2007 Oct;12(19-20):[http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T64-4PMT5XT-1-1&_cdi=5020&_user=16764&_pii=S1359644607003005&_origin=search&_coverDate=10%2F31%2F2007&_sk=999879980&view=c&wchp=dGLzVtz-zSkzS&md5=819e003053bf3a51219b92008546c264&ie=/sdarticle.pdf 838-43]. (pmid=17933685) | |||
# pmid=17766652 | |||
==P- | ==bile acid signaling== | ||
# Donnellan F, Keating N, Geoghegan P, Murray FE, Harvey BJ, Keely SJ. JNK mitogen-activated protein kinase limits calcium-dependent chloride secretion across colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1):G37-44. Epub 2009 Oct 29. PMID: 19875701 | |||
#1 | # Zucchini-Pascal N, de Sousa G, Pizzol J, Rahmani R. Pregnane X receptor activation protects rat hepatocytes against deoxycholic acid-induced apoptosis. Liver Int. 2010 Feb;30(2):284-97. Epub 2009 Sep 8. PMID: 19737350 | ||
# | # Sommerfeld A, Reinehr R, Häussinger D. Bile acid-induced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis. J Biol Chem. 2009 Aug 14;284(33):22173-83. Epub 2009 Jun 24. PMID: 19553664 | ||
#3 | # Takeuchi K, Shin-ya T, Nishio K, Ito F. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. FEBS J. 2009 Mar;276(5):1255-65. PMID: 19175673 | ||
# Ding G, Zhang A, Huang S, Pan X, Zhen G, Chen R, Yang T. ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol. 2007 Dec;293(6):F1889-97. Epub 2007 Sep 19. PMID: 17881465 | |||
# Cáceres M, Tobar N, Guerrero J, Smith PC, Martínez J. c-jun-NH2JNK mediates invasive potential and EGFR activation by regulating the expression of HB-EGF in a urokinase-stimulated pathway. J Cell Biochem. 2008 Feb 15;103(3):986-93. PMID: 17654528 | |||
# Reinehr R, Becker S, Wettstein M, Häussinger D. Involvement of the Src family kinase yes in bile salt-induced apoptosis. Gastroenterology. 2004 Nov;127(5):1540-57.PMID: 15521021 | |||
# Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, Amorino G, Valerie K, Sealy L, Engelhardt JF, Grant S, Hylemon PB, Dent P. Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol. 2003 May;23(9):3052-66. PMID: 12697808 | |||
# Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002 Apr;122(4):985-93. PMID: 11910351 | |||
# Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB, Dent P. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell. 2001 Sep;12(9):2629-45. PMID: 11553704 | |||
# Chen K, Vita JA, Berk BC, Keaney JF Jr. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J Biol Chem. 2001 May 11;276(19):16045-50. Epub 2001 Feb 27. PMID: 11278982 |
Latest revision as of 21:19, 19 January 2011
Feel free to add articles ...
Transporters general review
OATP family general review
OATP knockout models
Analysis: Methods
OATP1B3
P-glycoprotein (MDR1)
bile acid signaling
|